cyrilzakka/clinical-trials huggingface dataset:
Midodrine During Recovery From Septic Shock

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.


Eligibility Criteria:
Inclusion Criteria:

* admitted to intensive care unit
* diagnosis of septic shock on intravenous vasopressors
* stable/decreasing doses of intravenous vasopressors
* stable/improving organ function

Exclusion Criteria:

* allergy to midodrine
* multiple intravenous vasopressors
* increasing intravenous vasopressor requirements
* worsening organ dysfunction
* severe bradycardia
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung cancer (NSCLC).


Eligibility Criteria:
Inclusion Criteria:

* Histologically-confirmed Stage IV metastatic or recurrent (Stage IV) NSCLC of squamous histology
* Availability of formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue or a minimum of 15 (preferably 25) unstained tumor slides (cut within 1 week) suitable for Programmed death ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) expression/amplification assessments
* At least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry
* Adequate hematological, hepatic and renal function
* Estimated life expectancy of at least 3 months
* Can give signed informed consent
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Participants whose tumor disease harbors an activating EGFR mutation or ALK rearrangement. Participants with tumors of unknown EGFR or ALK status will require testing only in never smokers
* All participants with brain metastases with protocol defined exceptions
* Previous malignant disease (other than NSCLC) within the last 5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the participant was deemed to have been cured with no additional therapy required or anticipated to be required
* Active infection requiring systemic therapy
* Known history of human immunodeficiency virus or known acquired immunodeficiency syndrome
* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test positive)
* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
* Interstitial parenchymal lung disease
* Pregnancy or lactation
* Known alcohol or drug abuse as determined by the Investigator
* History of uncontrolled intercurrent illness
* Clinically significant (that is active) cardiovascular disease
* Known history of inflammatory colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis
* Any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements
* Prior/Concomitant Therapy as described in protocol
* Use of any investigational drug within 28 days before the start of study treatment
* Other protocol defined exclusion criteria could apply
Craniopharyngioma With Tumoral Hemorrhage

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

For each case, age, gender, smoking status, alcohol intake, past history, symptoms, blood pressure, blood cell count, blood biochemical tests, coagulation tests, hormone tests, radiological results, surgical treatment and the outcome at discharge were collected. The first test result after admission and before the operation was taken for the items of blood tests with multiple times in the analysis.

Eligibility Criteria:
Inclusion Criteria:

* receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital
* enter our hospital between January 2013 and February 2021

Exclusion Criteria:

* have a non-craniopharyngioma or unverified pathological diagnosis at discharge
* have received surgical or radiological treatment on the sellar region
* receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs
* combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission
* have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis

Our study aims at defining the role of circulating microparticles in the physiopathology of two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma (SSc). Microparticles might have an prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) are two rare and potentially life-threatening auto-immune systemic diseases. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Microparticles (MPs) are small extracellular vesicles formed from activated cells including endothelial cells and platelets. Preliminary data from our lab indicate that these MPs might play a key role in SLE and SSc physiopathology. In fact, MPs from patients with SLE aggregates with T regulator lymphocytes (LTregs) and decrease their activity, thereby promoting auto-immunity. Some works also indicate that MPs might cargo DNA to the immune system, also promoting auto-immunity. The investigators hypothesized that MPs levels might be a prognostic factor in SLE and SSc and that studying the molecular mechanisms involved could provide new therapeutic targets.

Our study will recruit 100 patients with SLE or SSc followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study circulating microparticles. Fundamental research will be realized on patients' sample to study molecular mechanisms involved.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with MPs to describe their potential prognostic role. Patients will be followed at regular intervals as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same times as those drawn for clinical purposes.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of systemic lupus erythematosus or systemic sclerosis;
* age ≥ 18 years;
* being affiliated to health insurance, willing to participate and to sign informed consent.

Exclusion Criteria:

* pregnant or breastfeeding women;
* patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Wisconsin Tobacco Quit Line Medicaid Incentive Evaluation

The study is designed to test the hypotheses that financial incentives can increase both participation in smoking cessation treatment and resulting cessation rates, when they are offered to BadgerCare Plus (Medicaid) smokers as part of their health care.

Previous research on providing incentives for healthy behaviors has shown that financial incentives can increase treatment participation and boost outcomes when they are tied to participation in evidence based treatments. However, most of this research has been done in laboratory settings and in relatively small clinical trials. This study is designed to test the hypotheses that incentives can increase both participation in smoking cessation treatment and resulting cessation rates, when they are offered to Wisconsin BadgerCare Plus (Medicaid) smokers as part of their health care. If successful, this treatment approach could be used more broadly to reduce the considerable financial and personal costs associated with smoking-related disease.

In this study, Medicaid-eligible smokers were recruited from primary care clinics and from callers to the Wisconsin Tobacco Quit Line (WTQL) with randomization a Control condition and an Incentive condition. All participants were offered five cessation calls from the WTQL and participants were encouraged by WTQL coaches to obtain cessation medication from their primary care providers. All participants received payment for completing a baseline assessment ($40) and a 6-month smoking test ($40). Only Incentive condition participants received additional compensation for taking counseling calls ($30 per completed call) and for biochemically-verified abstinence at the 6-month visit ($40).

Eligibility Criteria:
Inclusion Criteria:

* enrollment in Wisconsin Medicaid (BadgerCare Plus)
* resides in study area (one of 25 counties)
* 18 or older
* English or Spanish speaking
* has smoked daily (at least 5 cigarettes each day) over the last week
* willingness to attend visits at his/her PCC (primary care clinic) or go to a testing site at baseline and 6 months (2 times over a 6 month period), provide urine samples or participate in exhaled carbon monoxide testing, and complete follow-up phone calls from the WTQL
* willingness to inform the WTQL as to any change in address, phone number, clinic attended, or health plan.

Exclusion Criteria:

* not enrolled in Wisconsin Medicaid (BadgerCare Plus)
* not reside in study area
* less than 18 years of age
* not English or Spanish speaking
* does not smoke daily (at least 5 cigarettes each day) over the last week
* not willing to attend visits at his/her PCC (primary care clinic) or alternative testing site at baseline and 6 months (2 times over a 6 month period), provide urine or exhaled carbon monoxide samples, and complete follow-up phone calls.
* not willing to inform the WTQL as to any change in address, phone number, clinic attended, or health plan.
Changes in Shoulder Muscle Activation According to the Methods of Carrying Backpacks

To investigate change of shoulder muscles by measuring muscle activity according to the position of the backpack.

Most of modern people, including students and office workers, wear backpacks for a considerable amount of time. There have been prior studies on the change in muscle activity around the spine and shoulders muscles according to the weight of the backpack, but studies on the change in muscle activity according to the direction of the bag are insufficient. So this study is to evaluate the effect on the musculoskeletal system by comparing the activity of the muscles around the shoulder according to the anterior or posterior wearing of the backpack.

Muscles around the shoulder are composed of: Serratus anterior, trapezius(upper and lower) which control scapular movement and deltoid muscles which activate shoulder abduction directly. We would like to focus change of these muscles's activities when carrying a backpack according to the anterior or posterior direction and bilateral or unilateral.

To measure muscle activity, eight-channel electromyography (EMG) Using Nicolet EDX (Natus Medical Inc., San Carolos, CA, USA), surface EMG (sEMG) signal were used.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults from 20s to 50s

Exclusion Criteria:

* Restriction of joint motion range of shoulder and elbow
* Hisory of upper limb surgery in the past 6 months
* If there is an external wire such as a temporary external pacemaker or central line guide wire
SCRI Tissue Testing Registry

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Eligibility Criteria:
Inclusion Criteria:

* Patients must be \>= 18 years of age.
* Patients must be able to provide written informed consent.

Exclusion Criteria:

* Not Applicable
The Effect of a Scratch Off Prompt on Health Engagement

The goal of this project is to determine whether prompting the recipient of a health reminder mailing to scratch off targeted area.

The investigators will randomly assign individuals with different scratch off messages to 3 groups. The investigators are interested in whether the scratch off message will result in an increase in compliance with the recommended health behavior.

Eligibility Criteria:
Inclusion Criteria:

* Indications according to Spring 2011 CDC criteria for a blood pressure check
* Indications according to Spring 2011 CDC criteria for a cholesterol test
* Employee at partner corporation that implemented the study
Obesity and Diabetes Prevention Through Science Enrichment

Type 2 diabetes and obesity in children continue to increase at alarming rates with devastating results. However, both these metabolic diseases are largely preventable through adoption of a healthy lifestyle, an understanding of what happens to food in the body, energy balance and some simple aspects of glucose regulation. Can elementary school children be taught the knowledge and skills necessary to prevent type 2 diabetes and obesity? Children need to learn this essential knowledge and practice these important health behavior skills. Elementary school may be an ideal place to master this subject that is a direct and logical extension of current health curricula including nutrition and physical activity blended with science and math.

Biomedical scientists lead a classroom series of interactive, inquiry-based science and health explorations directed at type 2 diabetes, obesity and their prevention in three elementary schools serving children at high risk for type 2 diabetes. Diabetes knowledge was measured in children and parents at the beginning, end and 9 months after the end of the intervention using validated questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* Elementary school child in selected intervention or comparison classes/schools
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers.

Objectives are to determine:

1. the maximal tolerated dose of SC ND-0612
2. the steady state plasma concentration of LD and CD following SC ND-0612 administration.

Each treatment group will include 6 healthy volunteers. Dosing will be done in a sequential manner.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Caucasian males between 18 and 40 years (inclusive) of age
* Normal BMI (18.5-24.9)
* Subjects with negative urinary drugs of abuse, HIV, Hepatitis B or Hepatitis C serology tests
* Subjects must be able to adhere to the protocol requirements
* Subjects must provide written informed consent to participate in the study.

Exclusion Criteria:

* History of significant psychiatric disorder, neurological diseases or sleep disorders
* History of significant systemic diseases, by medical history or tests performed during screening examinations
* Clinically significant laboratory tests at screening
* History of drug or alcohol abuse.
* Allergy to levodopa, carbidopa or any inactive component of the test formulation.
* Subjects with dark skin
* Subjects with skin diseases or neoplasms
* Subjects with narrow-angle glaucoma
* Subjects with significant allergic response to other drugs.
* Presence of clinically significant scars or other skin disorders in the area of placement of the pump.
* Use of any prescription or over-the-counter (OTC) medications
* Subjects who donated blood or received blood, in the last 3 months
* Participation in another clinical trial in the last 30 days
* Subjects which do not have the ability to communicate well or will not adhere to the protocol procedures
High Dosage Vitamin D and Osteoporosis

Vitamin D and calcium are essential in the treatment and prevention of osteoporosis. What dosage of vitamin D which is the ideal one, is not yet clear. We want to test the hypothesis that high dosage of vitamin D (i.e. 6500 IU/d) is better than standard dosage (800 IU/d) in a randomized double-blind trial. We will include 400 postmenopausal otherwise healthy women with T-score \<= -2.0 in L2-4 or mean total hip. Everybody will receive calcium 1000 mg and vitamin D 800 IU every day. Half of the group will also receive vitamin D 40 000 IU/week, while the other half will have placebo. The study period is one year.


Eligibility Criteria:
Inclusion Criteria:

* bone mineral density in L2-4 or mean total hip with T-score \<= -2.0

Exclusion Criteria:

* current use of bisphosphonates, PTH-analogs, estrogen, SERM, p.o. steroids or use of any of these agents last year
* serum creatinin \>110 umol/L
* systolic blood pressure \>175 mmHg or diastolic blod pressure \>105
* serious disease (heart failure, angina pectoris, myocardial infarction, diabetes, mental reduction, granulomatous disease like sarcoidosis, cancer)
* kidney stone
* serum calcium \> 2.55 mmol/L
* suspect primary hyperparathyroidism with serum calcium \>2.50 mmol/L combined with PTH \> 5.0 mmol/L or serum calcium \> 2.45 mmol/L combined with PTH \>= 7.0 pmol/L
Prospective Registry of 3-dimensional Virtual Treatment Planning of Orthognathic Surgery

Orthognathic surgery or corrective jaw surgery is indicated for conditions of the jaw and face that are related to structure or growth malfunctioning, orthodontic problems, or co-morbidities associated with skeletal disfigurement.

Imaging is crucial in the assessment and treatment planning of orthognathic surgery patients. Until recently, two-dimensional (2D) imaging, through cephalometry, was standard practice. However, it showed several limitations. The introduction of the cone-beam computed tomography (CBCT) enabling three-dimensional (3D) imaging has caused a paradigm shift. Though widespread implementation in routine practice is not yet present. Our department is one of the pioneers in the world of 3D virtual treatment planning for orthognathic surgery. The "triple CBCT scan procedure" has been developed in-house and implemented already in 2009.

The investigators aim to develop a prospective database registering 3D treatment planning data of all consecutive patients eligible for orthognathic surgery, performed by Prof. Swennen. Patient demographics, detailed virtual 3D treatment planning parameters and orthognathic surgery data are being collected during consecutive visits within the framework of routine practice.

Development of a database registering 3D virtual treatment planning data of orthognathic surgery, will provide more information about potential patient, virtual planning and surgical factors influencing postoperative accuracy of jaw correction, long-term stability of the jawbone, long-term condylar resorption, or soft tissue response. In general, it could provide answers on research questions that have been examined in prior studies on 2D-imaging, but can now be re-examined in case of 3D-imaging. Moreover, registration of those results could function as a measurement of quality of care, or could be used for sample size calculation for future large multicenter prospective trials.


Eligibility Criteria:
Inclusion Criteria:

* Patients of all ages
* Both female and male patients
* Patients should present themselves at the Department of Oral and Maxillofacial Surgery of the General Hospital Saint-John Bruges for orthognathic surgical treatment
* Patients receive standardized cone-beam computed tomography (CBCT) image acquisition (i-CAT, Imaging sciences international, inc, Hatfield, USA) according to the "triple" CBCT scan protocol
* Patients' orthognathic surgery should be prepared by a standardized setup of an augmented 3D virtual patient model in centric relation, with detailed occlusal and intercuspidation data using the "triple" voxel-based rigid registration protocol (Maxilim v2.2.2., Nobel Biocare c/o Medicim nv, Mechelen, Belgium)
* Patients' surgery should be prepared preoperatively through 3D virtual planning steps performed with the same software, by the same surgeon (GS)
* Patients should be operated by the same surgeon (GS)

Exclusion Criteria:

* All patients that do not fit in the abovementioned description
* Patients with posttraumatic deformity
* Patients with congenital deformity
* Patients with preprosthetic indication
Socket Shield vs Conventional Immediate Implant

eighteen implants will be placed in patients with non-restorable maxillary teeth in the aesthetic area.the recruited patients will be divided into two groups .group 1 will undergo socket shield technique with immediate temporization ,while group 2 will undergo conventional immediate implant placement with immediate temporization. to compare bone loss and aesthetic outcomes in the two techniques.


Eligibility Criteria:
Inclusion Criteria:

* Patients with non-restorable maxillary anterior teeth in the esthetic zone indicated for implant placement.
* Both sexes.
* No intraoral soft and hard tissue pathology
* No systemic condition that contraindicate implant placement

Exclusion Criteria:

* Heavy smokers more than 20 cigarettes per day.
* Patients with systemic disease that may affect normal healing.
* Psychiatric problems
* Disorders to implant are related to history of radiation therapy to the head and neck neoplasia